Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion.

Abstract

Unlike 5q syndrome, the 5q deletion in acute myeloid leukemia AML) has been associated with a poor outcome [1]. However, a atient subgroup has been identified with more than one normal etaphase in cytogenetic studies and no previous hematologic disrder, in whom the prognosis is similar to that in patients with a ormal karyotype [2]. Clinical trials with… (More)
DOI: 10.1016/j.leukres.2008.11.017

Topics

1 Figure or Table

Cite this paper

@article{Pearrubia2009HematologicAC, title={Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion.}, author={Mar{\'i}a Jes{\'u}s Pe{\~n}arrubia and Luz A Silvestre and Joaquina Conde and Alberto Cantalapiedra and Luis J Garcia Frade}, journal={Leukemia research}, year={2009}, volume={33 6}, pages={e8-9} }